Seattle Genetics Stock Rallied
Seattle Genetics (SGEN) financial results started with Clay Siegall, Ph.D., President and Chief Executive Officer of the firm stating the following:

• Seattle Genetics achieved record net sales in the U.S. and Canada for Adcetris, reflecting growth in frontline CD30-expressing peripheral T-cell lymphomas as well as frontline advanced Hodgkin lymphoma.  
• The Biologics . . .
  
  This content is for paid subscribers.
  Please click here to subscribe or here to log in.
  Today’s Highlights

  Seagen Inc (SGEN)

  July 17, 2019
  Tweet Pin It